Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies

Critical Reviews in Oncology/Hematology

Volumn 38, Issue 1, 2001, Pages 25-35

  Richman, Carol M ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; MUC 1 antibodies; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; CELL SURFACE PROTEIN; EPITOPE; GLYCOPROTEIN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BRE 3; MONOCLONAL ANTIBODY M 170; MUCIN; PROTEIN MUC 1; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG POTENTIATION; DRUG TARGETING; HUMAN; METASTASIS; MINIMAL RESIDUAL DISEASE; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOSENSITIZATION; REVIEW; STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 0035117356     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00136-0     Document Type: Review

References (78)

1. Trials and tribulations: oncological antibody imaging comes to the fore
2. A revolution in the treatment of non-Hodgkin's lymphoma
3. The development of monoclonal antibodies for the therapy of cancer
4. Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies
5. Treatment of B cell malignancies with I-131 Lym-1 monoclonal antibodies
6. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
7. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
8. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies
9. Iodine-131 Anti-B1 antibody for non-Hodgkin's lymphoma (NHL): overall clinical trial experience
10. I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions
11. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
12. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
13. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody
14. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial
15. Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer
16. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 (cT84.66) anti-carcinoembryonic antigen antibody and autologous hematopietic stem cell support in patients with anti-carcinoembryonic antigen-producing metastatic breast cancer
17. 90Y monoclonal antibodies 170H.82 with autologous stem cell support and cyclosporin A
18. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin
19. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (MUC-1) protein core
20. 99mTc SM3 radioimmunoscintigraphy
21. Radioimmunolocalization of breast carcinoma using BrE-3 monoclonal antibody: phase I study
22. Radioimmunolocalization of primary and metastatic breast cancer
23. Breast tumor radioimmunodetection with a 111-In-labeled monoclonal antibody (MA5) against a mucin-like antigen
24. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3
25. 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial
26. 90Y MAB 170H.82 with autologous stem cell support and cyclosporin A
27. A novel anti-breast epithelial mucin MoAb (BrE-3)
28. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study
29. Characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule
30. Radioimmunotherapy in the treatment of metastatic breast cancer: an overview
31. 111In
32. New developments in monoclonal antibodies for cancer detection and therapy
33. Antibody imaging in breast cancer
34. Cloning and expression of the tumor-associated antigen L6
35. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells
36. The biologic window for chimeric L6 radioimmunotherapy
37. Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy
38. Tumor pretargeting: almost the bottom line [editorial; comment]
39. A revised schema for calculating the absorbed dose from biologically distributed radionuclides
40. 'S' absorbed dose per unit cumulated activity for selected radionuclides and organs
41. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3)
42. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts
43. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates
44. Comparison of DOTA-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2IT-BAD-ChL6 in breast cancer xenografts
45. Yttrium-90/Indium-111-DOTA-peptide-Chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer
46. Cathepsin substrates as cleavable peptide linkers on bioconjugates, selected from a fluorescence quench combinatorial library
47. Total solid-phase synthesis of DOTA-functionalized peptides for radioimmunotherapy
48. Quantitative phamacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients
49. Requirements for a treatment planning system for radioimmunotherapy
50. Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates
51. Innovations in three-dimensional treatment planning and quality assurance
52. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides
53. Three-dimensional dosimetry for radioimmunotherapy treatment planning
54. 131I-labeled anti-carcinoembryonic antigen antibodies
55. Monte Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system
56. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody
57. High-dose radioimmunotherapy of B cell lymphomas
58. Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation
59. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid carcinoma using 131-I-MN-14 F(ab)2 anti-carcinoembryonic antigen (CEA) monoclonal antibody and autologous hematopoietic stem rescue (AHSCR)
60. The MIRD perspective in 1999
61. Practical simplifications for radioimmunotherapy dosimetric models
62. Practical determination of organ S values for individual patients for therapy
63. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions
64. Radioimmunotherapy for breast cancer: systemic tumor-targeted irradiation
65. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer
66. High-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous hematopoietic stem cell support (AHSCS) in patients with metastatic breast cancer
67. A phase I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to supress the immune response
68. Human anti-mouse antibody suppression with cyclosporin A
69. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients
70. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells
71. 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model
72. Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters
73. Mechanism of action of taxol
74. Concurrent paclitaxel and radiation therapy for solid tumors
75. Intraperitoneal radioimmunotherapy for refractory epithelial ovarian cancer with 177Lu-CC49
76. Improving the tumor specificity and retention of antibody-based molecules
77. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics